Corrigendum to "Androgens and prostate cancer" [Best Practice & Research Clinical Endocrinology & Metabolism 2008; 22 (4): 601-613] (DOI:10.1016/j.beem.2008.06.002);Androgens and prostate cancer risk

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 4, 2008, Pages 601-613

  Wirén, Sara ^b   Stattin, Pär ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b NONE

Author keywords

androgens; finasteride; late onset hypogonadism; prostatic neoplasms; testosterone; testosterone replacement therapy

Indexed keywords

ANDROGEN; ANDROSTANEDIONE; ANDROSTANOLONE; CYTOCHROME P450 17; DUTASTERIDE; ESTRADIOL; FINASTERIDE; PLACEBO; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; DRUG SAFETY; GENETIC VARIABILITY; HORMONE INHIBITION; HUMAN; HYPOGONADISM; NONHUMAN; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; SYMPTOMATOLOGY;

EID: 54349095266     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.02.002     Document Type: Erratum

References (82)

1. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. Journal of the National Cancer Institute. Monographs 27 (2000) 39-66
2. Hsing A.W., Reichardt J.K., and Stanczyk F.Z. Hormones and prostate cancer: current perspectives and future directions. Prostate 52 3 (2002 Aug 1) 213-235
3. Platz E.A., and Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 92 4 (2004 Nov) 237-253
4. Bladou F., Vessella R.L., Buhler K.R., et al. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. International Journal of Cancer 67 6 (1996 Sep 17) 785-790
5. Lucia M.S., Bostwick D.G., Bosland M., et al. Workgroup I: rodent models of prostate cancer. Prostate 36 1 (1998 Jun 15) 49-55
6. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Research 37 6 (1977 Jun) 1929-1933
7. Bostwick D.G., Burke H.B., Djakiew D., et al. Human prostate cancer risk factors. Cancer 101 Suppl. 10 (2004 Nov 15) 2371-2490
8. Keller E.T., Ershler W.B., and Chang C. The androgen receptor: a mediator of diverse responses. Frontiers in Bioscience: A Journal and Virtual Library 1 (1996 Mar 1) d59-d71
9. Kaarbo M., Klokk T.I., and Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 29 12 (2007 Dec) 1227-1238
10. Zhou Z.X., Lane M.V., Kemppainen J.A., et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Molecular Endocrinology 9 2 (1995 Feb) 208-218
11. Gao W., Bohl C.E., and Dalton J.T. Chemistry and structural biology of androgen receptor. Chemical Reviews 105 9 (2005 Sep) 3352-3370
12. Russell D.W., and Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 (1994) 25-61
13. Amory J.K., Wang C., Swerdloff R.S., et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. The Journal of Clinical Endocrinology and Metabolism 92 5 (2007 May) 1659-1665
14. Rittmaster R.S., Zwicker H., Thompson D.L., et al. Androstanediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. The Journal of Clinical Endocrinology and Metabolism 76 4 (1993 Apr) 977-982
15. Norman R.W., Coakes K.E., Wright A.S., et al. Androgen metabolism in men receiving finasteride before prostatectomy. The Journal of Urology 150 5 Pt 2 (1993 Nov) 1736-1739
16. Nomura A., Heilbrun L.K., Stemmermann G.N., et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Research 48 12 (1988 Jun 15) 3515-3517
17. Nomura A.M., Stemmermann G.N., Chyou P.H., et al. Serum androgens and prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 5 8 (1996 Aug) 621-625
18. Barrett-Connor E., Garland C., McPhillips J.B., et al. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Research 50 1 (1990 Jan 1) 169-173
19. Hsing A.W., and Comstock G.W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2 1 (1993 Jan-Feb) 27-32
20. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27 1 (1995 Jul) 25-31
21. Gann P.H., Hennekens C.H., Ma J., et al. Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 88 16 (1996 Aug 21) 1118-1126
22. Guess H.A., Friedman G.D., Sadler M.C., et al. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiology, Biomarkers & Prevention 6 1 (1997 Jan) 21-24
23. Vatten L.J., Ursin G., Ross R.K., et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiology, Biomarkers & Prevention 6 11 (1997 Nov) 967-969
24. Dorgan J.F., Albanes D., Virtamo J., et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiology, Biomarkers & Prevention 7 12 (1998 Dec) 1069-1074
25. Heikkila R., Aho K., Heliovaara M., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86 2 (1999 Jul 15) 312-315
26. Mohr B.A., Feldman H.A., Kalish L.A., et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57 5 (2001 May) 930-935
27. Stattin P., Lumme S., Tenkanen L., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. International Journal of Cancer 108 3 (2004 Jan 20) 418-424
28. Chen C., Weiss N.S., Stanczyk F.Z., et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiology, Biomarkers & Prevention 12 12 (2003 Dec) 1410-1416
29. Ozasa K., Nakao M., Watanabe Y., et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Science 95 1 (2004 Jan) 65-71
30. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiology, Biomarkers & Prevention 14 5 (2005 May) 1262-1269
31. Parsons J.K., Carter H.B., Platz E.A., et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiology, Biomarkers & Prevention 14 9 (2005 Sep) 2257-2260
32. Severi G., Morris H.A., MacInnis R.J., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 1 (2006 Jan) 86-91
33. Travis R.C., Key T.J., Allen N.E., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer 121 6 (2007 Sep 15) 1331-1338
34. Weiss JM, Huang WY, Rinaldi S, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. International Journal of Cancer, in press.
35. Wiren S., Stocks T., Rinaldi S., et al. Androgens and prostate cancer risk: a prospective study. Prostate 67 11 (2007 Aug 1) 1230-1237
36. Roddam A.W., Allen N.E., Appleby P., et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 100 3 (2008 Feb 6) 170-183
37. Kaaks R., Lukanova A., Rinaldi S., et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. European Journal of Cancer Prevention 12 4 (2003 Aug) 309-315
38. MacInnis R.J., and English D.R. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17 8 (2006 Oct) 989-1003
39. Hsing A.W., Sakoda L.C., and Chua Jr. S. Obesity, metabolic syndrome, and prostate cancer. The American Journal of Clinical Nutrition 86 3 (2007 Sep) s843-s857
40. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 4 8 (2004 Aug) 579-591
41. Allen N.E., Appleby P.N., Davey G.K., et al. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 13 4 (2002 May) 353-363
42. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. Journal of Urology 163 3 (2000 Mar) 824-827
43. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 1 (2001 Apr) 52-58
44. Giwercman A., Richiardi L., Kaijser M., et al. Reduced risk of prostate cancer in men who are childless as compared to those who have fathered a child: a population based case-control study. International Journal of Cancer 115 6 (2005 Jul 20) 994-997
45. Jorgensen K.T., Pedersen B.V., Johansen C., et al. Fatherhood status and prostate cancer risk. Cancer 112 4 (2008 Feb 15) 919-923
46. Miller L.R., Partin A.W., Chan D.W., et al. Influence of radical prostatectomy on serum hormone levels. Journal of Urology 160 2 (1998 Aug) 449-453
47. Madersbacher S., Schatzl G., Bieglmayer C., et al. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology 60 5 (2002 Nov) 869-874
48. Crawford E.D., Barqawi A.B., O'Donnell C., et al. The association of time of day and serum testosterone concentration in a large screening population. BJU International 100 3 (2007 Sep) 509-513
49. Harman S.M., Metter E.J., Tobin J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology and Metabolism 86 2 (2001 Feb) 724-731
50. Vermeulen A., and Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. The Journal of Clinical Endocrinology and Metabolism 74 4 (1992 Apr) 939-942
51. Anderson P.H., Fukushima K., and Schiller H.S. Radioimmunoassay of plasma testosterone, with use of polyethylene glycol to separate antibody-bound and free hormone. Clinical Chemistry 21 6 (1975 May) 708-714
52. Vermeulen A., Verdonck L., and Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. The Journal of Clinical Endocrinology and Metabolism 84 10 (1999 Oct) 3666-3672
53. Giton F., Fiet J., Guechot J., et al. Serum bioavailable testosterone: assayed or calculated?. Clinical Chemistry 52 3 (2006 Mar) 474-481
54. Key T.J., Appleby P.N., Reeves G.K., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 95 16 (2003 Aug 20) 1218-1226
55. Ebrahim S., and Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?. Human Genetics 123 1 (2008 Feb) 15-33
56. Lindstrom S., Zheng S.L., Wiklund F., et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 66 16 (2006 Dec 1) 1729-1743
57. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 22 15 (1994 Aug 11) 3181-3186
58. Lindstrom S., Adami H.O., Balter K.A., et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clinical Cancer Research 13 17 (2007 Sep 1) 5156-5161
59. Chokkalingam A.P., Stanczyk F.Z., Reichardt J.K., et al. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Frontiers in Bioscience: A Journal and Virtual Library 12 (2007) 3436-3460
60. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine 349 3 (2003 Jul 17) 215-224
61. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute 98 16 (2006 Aug 16) 1128-1133
62. Thompson I.M., Lucia M.S., Redman M.W., et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. Journal of Urology 178 1 (2007 Jul) 107-109 discussion 10
63. Thompson I.M., Klein E.A., Lippman S.M., et al. Prevention of prostate cancer with finasteride: US/European perspective. European Urology 44 6 (2003 Dec) 650-655
64. Cohen Y.C., Liu K.S., Heyden N.L., et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 99 18 (2007 Sep 19) 1366-1374
65. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 99 18 (2007 Sep 19) 1375-1383
66. Thomas L.N., Douglas R.C., Lazier C.B., et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. Journal of Urology 179 1 (2008 Jan) 147-151
67. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. Journal of Urology 172 4 Pt 1 (2004 Oct) 1314-1317
68. Nieschlag E., Swerdloff R., Behre H.M., et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Journal of Andrology 27 2 (2006 Mar-Apr) 135-137
69. Miner M.M., and Seftel A.D. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?. International Journal of Clinical Practice 61 4 (2007 Apr) 622-632
70. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299 1 (2008 Jan 2) 39-52
71. Morgentaler A., and Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68 6 (2006 Dec) 1263-1267
72. Brand T.C., Canby-Hagino E., and Thompson I.M. Testosterone replacement therapy and prostate cancer: a word of caution. Current Urology Reports 8 3 (2007 May) 185-189
73. Hwang J.J., Dharmawardana P.G., Uchio E.M., et al. Prostate cancer in Klinefelter syndrome during hormonal replacement therapy. Urology 62 5 (2003 Nov) 941
74. Bydder S.A., Joseph D.J., Weinstein S., et al. Prostate cancer following testosterone replacement in Klinefelter syndrome. ANZ Journal of Surgery 77 1-2 (2007 Jan-Feb) 93-94
75. Swerdlow A.J., Schoemaker M.J., Higgins C.D., et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. Journal of the National Cancer Institute 97 16 (2005 Aug 17) 1204-1210
76. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 350 5 (2004 Jan 29) 482-492
77. Gould D.C., Feneley M.R., and Kirby R.S. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy. BJU International 98 1 (2006 Jul) 1-4
78. Bostwick D.G., Pacelli A., and Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 29 2 (1996 Aug) 117-134
79. Rhoden E.L., and Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. Journal of Urology 170 6 Pt 1 (2003 Dec) 2348-2351
80. Raynaud J.P., Legros J.J., Rollet J., et al. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. The Journal of Steroid Biochemistry and Molecular Biology 109 1-2 (2008) 168-176
81. Behre H.M., Bohmeyer J., and Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clinical Endocrinology 40 3 (1994 Mar) 341-349
82. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 19 (2006 Nov 15) 2351-2361